Mr. Hedquist offers a diverse set of skills and experience, gained over more than a decade of working within the pharmaceutical and biotech industry. He specializes in developing and implementing public affairs strategies and campaigns designed to influence healthcare policy. His experience includes work with policy makers, patient advocacy groups and industry partners across several therapeutic areas and rare diseases. ​

Prior to joining Edelman, Mr. Hedquist worked internationally for the Danish pharmaceutical company Novo Nordisk A/S and its biotech sister company Novozymes. His work focused on advancing strategic projects and product launches primarily within diabetes and hemophilia. ​

As part of Novo Nordisk’s government affairs office in Washington, D.C., Mr. Hedquist specialized in state level policy where he focused on diabetes prevention legislation and access to obesity treatments in collaboration with state legislative groups and patient advocacy organizations. Additionally, he led company efforts on the Trans-Atlantic Trade and Investment Partnership trade deal, in partnership with industry peers and the Danish and American Embassies. ​

Mr. Hedquist holds a bachelor’s degree in Political Science from Brigham Young University, as well a master’s in Business Administration (MBA) and master’s in International Trade and Investment Policy from the George Washington University.